The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eli Lilly's Zepbound is set to dominate the global obesity market, offering new hope with its groundbreaking treatment for ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

and Eli Lilly’s drug is more potent, and perhaps negotiations with national health services will also make it more ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...